Two-year Opioid Prescription Trends in Local Sanitary Agency Naples 3 South, Campania Region, Italy. Descriptive Analyses and AI-based Translational Perspectives.

IF 1.1 Q4 MEDICINE, RESEARCH & EXPERIMENTAL
Translational Medicine at UniSa Pub Date : 2024-02-27 eCollection Date: 2024-01-01 DOI:10.37825/2239-9747.1047
Marco Cascella, Maurizio Capuozzo, Francesco Ferrara, Alessandro Ottaiano, Francesco Perri, Francesco Sabbatino, Valeria Conti, Vittorio Santoriello, Alfonso Maria Ponsiglione, Maria Romano, Francesco Amato, Ornella Piazza
{"title":"Two-year Opioid Prescription Trends in Local Sanitary Agency Naples 3 South, Campania Region, Italy. Descriptive Analyses and AI-based Translational Perspectives.","authors":"Marco Cascella, Maurizio Capuozzo, Francesco Ferrara, Alessandro Ottaiano, Francesco Perri, Francesco Sabbatino, Valeria Conti, Vittorio Santoriello, Alfonso Maria Ponsiglione, Maria Romano, Francesco Amato, Ornella Piazza","doi":"10.37825/2239-9747.1047","DOIUrl":null,"url":null,"abstract":"<p><strong>Aims: </strong>This study delves into the two-year opioid prescription trends in the Local Sanitary Agency Naples 3 South, Campania Region, Italy. The research aims to elucidate prescribing patterns, demographics, and dosage categories within a population representing 1.7% of the national total. Perspectives on artificial intelligence research are discussed.</p><p><strong>Methods: </strong>From the original dataset, spanning from January 2022 to October 2023, we processed multiple variables including demographic data, medications, dosages, drug consumption, and administration routes. The dispensing quantity was calculated as defined daily doses (DDD).</p><p><strong>Results: </strong>The analysis reveals a conservative approach to opioid therapy. In subjects under the age of 20, prescriptions accounted for 2.1% in 2022 and declined to 1.4% in 2023. The drug combination paracetamol/codeine was the most frequently prescribed, followed by tapentadol. Approximately two-thirds of the consumption pertains to oral formulations. Transdermal formulations were 15% (fentanyl 9.8%, buprenorphine 5.1%) in 2022; and 16.6% (fentanyl 10%, buprenorphine 6.6%) in 2023. These data were confirmed by the DDD analysis. The trend analysis demonstrated a significant reduction ( <i>p</i> < 0.001) in the number of prescribed opioids from 2022 to 2023 in adults (40-69 years). The study of rapid-onset opioids (ROOs), drugs specifically used for breakthrough cancer pain, showed higher dosage (>267 mcg) consumption among women, whereas a lower dosage (<133 mcg) was calculated for men. Fentanyl pectin nasal spray accounted for approximately one-fifth of all ROOs.</p><p><strong>Conclusion: </strong>Despite limitations, the study provides valuable insights into prescribing practices involving an important study population. The findings underscore the need for tailored approaches to prescribing practices, recognizing the complexities of pain management in different contexts. This research can contribute to the ongoing discourse on opioid use, advocating for innovative strategies that optimize therapeutic outcomes while mitigating potential risks.</p>","PeriodicalId":54170,"journal":{"name":"Translational Medicine at UniSa","volume":null,"pages":null},"PeriodicalIF":1.1000,"publicationDate":"2024-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10980290/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Translational Medicine at UniSa","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.37825/2239-9747.1047","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0

Abstract

Aims: This study delves into the two-year opioid prescription trends in the Local Sanitary Agency Naples 3 South, Campania Region, Italy. The research aims to elucidate prescribing patterns, demographics, and dosage categories within a population representing 1.7% of the national total. Perspectives on artificial intelligence research are discussed.

Methods: From the original dataset, spanning from January 2022 to October 2023, we processed multiple variables including demographic data, medications, dosages, drug consumption, and administration routes. The dispensing quantity was calculated as defined daily doses (DDD).

Results: The analysis reveals a conservative approach to opioid therapy. In subjects under the age of 20, prescriptions accounted for 2.1% in 2022 and declined to 1.4% in 2023. The drug combination paracetamol/codeine was the most frequently prescribed, followed by tapentadol. Approximately two-thirds of the consumption pertains to oral formulations. Transdermal formulations were 15% (fentanyl 9.8%, buprenorphine 5.1%) in 2022; and 16.6% (fentanyl 10%, buprenorphine 6.6%) in 2023. These data were confirmed by the DDD analysis. The trend analysis demonstrated a significant reduction ( p < 0.001) in the number of prescribed opioids from 2022 to 2023 in adults (40-69 years). The study of rapid-onset opioids (ROOs), drugs specifically used for breakthrough cancer pain, showed higher dosage (>267 mcg) consumption among women, whereas a lower dosage (<133 mcg) was calculated for men. Fentanyl pectin nasal spray accounted for approximately one-fifth of all ROOs.

Conclusion: Despite limitations, the study provides valuable insights into prescribing practices involving an important study population. The findings underscore the need for tailored approaches to prescribing practices, recognizing the complexities of pain management in different contexts. This research can contribute to the ongoing discourse on opioid use, advocating for innovative strategies that optimize therapeutic outcomes while mitigating potential risks.

意大利坎帕尼亚大区南那不勒斯 3 号地方卫生机构两年阿片类药物处方趋势。描述性分析和基于人工智能的转化视角。
目的:本研究深入探讨了意大利坎帕尼亚大区那不勒斯三区南部地方卫生局两年来的阿片类药物处方趋势。研究旨在阐明占全国总人数 1.7% 的人群中的处方模式、人口统计学和剂量类别。研究还讨论了人工智能研究的前景:从 2022 年 1 月到 2023 年 10 月的原始数据集中,我们处理了多个变量,包括人口统计学数据、药物、剂量、药物消耗量和给药途径。配药量按定义日剂量(DDD)计算:分析结果表明,阿片类药物治疗采取了保守疗法。2022 年,20 岁以下受试者的处方占 2.1%,2023 年降至 1.4%。扑热息痛/可待因复方制剂是最常用的处方药,其次是他喷他多。约三分之二的消费量与口服制剂有关。2022年,透皮制剂的消费量为15%(芬太尼9.8%,丁丙诺啡5.1%);2023年为16.6%(芬太尼10%,丁丙诺啡6.6%)。DDD 分析证实了这些数据。趋势分析表明,从 2022 年到 2023 年,成人(40-69 岁)的阿片类药物处方数量大幅减少(p < 0.001)。对专门用于治疗突破性癌痛的速效阿片类药物(ROOs)的研究显示,女性的用药量(>267 毫克)较高,而女性的用药量(>260 毫克)较低(结论:女性的用药量较高,而男性的用药量较低):尽管存在局限性,但这项研究为了解涉及重要研究人群的处方做法提供了宝贵的见解。研究结果强调,有必要采取有针对性的处方做法,同时认识到不同情况下疼痛管理的复杂性。这项研究可为当前有关阿片类药物使用的讨论做出贡献,倡导在减轻潜在风险的同时优化治疗效果的创新策略。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Translational Medicine at UniSa
Translational Medicine at UniSa MEDICINE, RESEARCH & EXPERIMENTAL-
自引率
0.00%
发文量
8
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信